Voyager Therapeutics, Inc. (NASDAQ:VYGR) Short Interest Update

Voyager Therapeutics, Inc. (NASDAQ:VYGR) saw a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 2,440,000 shares, a decrease of 17.3% from the October 31st total of 2,950,000 shares. Based on an average daily volume of 562,900 shares, the days-to-cover ratio is currently 4.3 days.

Insider Buying and Selling

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.53% of the stock is currently owned by corporate insiders.

Institutional Trading of Voyager Therapeutics

Institutional investors have recently made changes to their positions in the business. Great Point Partners LLC acquired a new position in Voyager Therapeutics during the 2nd quarter valued at about $12,668,000. Erste Asset Management GmbH acquired a new position in shares of Voyager Therapeutics during the third quarter valued at about $6,192,000. Vanguard Group Inc. raised its position in shares of Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after purchasing an additional 702,030 shares during the last quarter. Armistice Capital LLC raised its position in shares of Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after purchasing an additional 528,000 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in Voyager Therapeutics by 32.4% in the 2nd quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock worth $8,063,000 after purchasing an additional 249,659 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Wall Street Analysts Forecast Growth

VYGR has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Leerink Partners assumed coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock. Finally, StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 18th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $17.50.

Voyager Therapeutics Stock Performance

Shares of Voyager Therapeutics stock opened at $6.86 on Monday. Voyager Therapeutics has a one year low of $5.19 and a one year high of $11.72. The company has a market capitalization of $374.76 million, a PE ratio of 9.66 and a beta of 0.89. The company has a 50-day simple moving average of $6.51 and a two-hundred day simple moving average of $7.29.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the previous year, the business posted ($0.59) EPS. On average, equities analysts predict that Voyager Therapeutics will post -0.92 earnings per share for the current fiscal year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.